$WBA 2025 F/Y GUIDANCE 🔸 Sees ADJ EPS $1.40 to $1.80, EST $1.73 🔸 Sees sales $147B to $151B, EST $146.9B 🔸 Sees ADJ operating income $1.6B to $2.0B, EST $1.89B RESULTS: Q4 🔸 ADJ EPS $0.39 vs. $0.67 y/y, EST $0.36 🔸 International sales $5.97B, +3.2% y/y, EST $5.84B 🔸 Sales $37.55B, +6% y/y, EST $35.56B 🔸 ADJ gross margin 16.9% vs. 18.6% y/y, EST 17.6% 🔸 US Retail Pharmacy Sales $29.47B, +6.5% y/y, EST $27.48B 🔸 US Healthcare Sales $2.11B, +7.2% y/y, EST $2.15B 🔸 ADJ gross profit $6.33B, -4% y/y, EST $6.24B 🔸 ADJ operating income $424M, -38% y/y, EST $396M